ClinGen Cardiomyopathy Variant Curation Expert Panel

Date	Your Name	Do you work for a laboratory that offers fee-for-service testing related to the work of your Expert Panel?	Have you made substantial contributions to the literature implicating a gene:disease relationship that relates to the work of your Expert Panel?		Do you have any other existing or planned independent curation efforts that will potentially overlap with the scope of your ClinGen work? If so, please describe:	Please disclose any other relevant conflicts of interest (e.g. patents, intellectual property ownership, or paid consultancies related to any variants or genes associated with the work of your Expert Panel):
	Open-Ended Response	Response	Response	If yes, please list the genes:	Open-Ended Response	Open-Ended Response
2019-01-29 23:34:24	Lucas Bronicki	No	No		Our lab has adopted allele frequency thresholds, based on Whiffin et al and similar to those established for MYH7, to aid interpretation of variants in the cardiomyopathy genes on our NGS panels.	none
2019-01-29 13:15:18	Katrina Kotzer	Yes	No		No	none
2018-09-27 8:20:10	Audrey Schaffer	No	No			Regarding question #2, I just wanted to add that while our laboratory receives is compensated by MOHTLC for cardiomyopathy testing on a fee-for-service basis, this is not a commercial arrangement.
2018-08-29 8:44:02	Arjun (Raj) Manrai	No	No		n/a	n/a
2018-07-18 0:52:18	Jessica Woodley	Yes	No		No	
2018-07-24 7:58:03	Peter van Tintelen	No	Yes	maybe DES, PLN	no	none
2018-06-20 5:24:11	Jan Jongbloed	Yes	Yes	CALR3	no	no other conflict of interest
2018-06-14 19:30:55	Charlotte Burns	No	No		Nil	Nil
2018-06-14 10:52:21	Heather Zimmermann	Yes	No		I routinely assess cardio variants we detect at my institution, and some of them are in MYH7.	
2018-06-14 10:45:13	Kate Thomson	Yes	No		I am involved in research projects which seek to use case control analyses to better understand rare variation in inherited cardiac disease genes.	
2018-06-14 10:32:19	Michelle Kluge	Yes	No			
2018-06-14 10:23:38	Emily Qian	Yes	No		No	
2018-06-14 10:18:06	Matthew Sdano	Yes	No		No.	
2018-04-30 16:34:14	Tami Johnston	Yes	No			
2018-04-03 13:46:32	Melissa A. Kelly	No	No		No	
2018-03-21 5:45:00	Ray Hershberger	No	Yes	LMNA, BAG3, lesser for a few others.	we have an NIH funded study to curate variants in DCM genes, but I don't think a conflict as we leverage clingen approaches, which will be cited now that the MYH7 paper is published.	none.
2018-03-17 21:14:42	Sharlene Day	No	No		No	
2018-03-15 19:54:19	Joseph Maleszewski	No	No			
2018-02-23 2:09:49	Chris Semsarian	No	Yes	ACTN2, MYH7, MYBPC3, TNNI2	no	Nil
2018-03-15 14:07:56	Patricia Arscott	No	No			none
2018-03-15 5:03:41	Heather McLaughlin	Yes	No		No	N/A
2018-02-22 15:08:34	chris antolik	Yes	No		no	none
2018-03-14 12:20:50	Daniela Macaya	Yes	No		N/A	N/A
2018-02-23 12:28:15	Ana Morales	No	No		No existing or planned independent curation effort.	N/A

2018-03-14 11:33:27	Gabriele Richard	Yes	No			
2018-03-14 11:28:05	Linnea Baudhuin	Yes	No		no	none
2018-03-13 13:27:51	Matteo Vatta	Yes	No			employment and stocks from Invitae Corporation
2018-03-13 11:31:23	Tami Johnston	Yes	No			
2018-02-26 8:16:03	Allison Cirino	No	No		No	
2018-02-26 8:01:49	Carolyn Ho	No	No		no	n/a
2018-02-25 20:15:53	Jodie Ingles	No	Yes	Sarcomere genes mostly	We regularly curate research variants and provide reports to patients. We also review our patients variants from laboratories and reclassify these as appropriate.	
2018-02-24 16:46:28	Colleen Caleshu	No	No		no	Intellectual property, royalties - genome interpretation technology Stockholder – Personalis Consultant, Advisor - Phosphorus Consultant, Advisor - Recombine Advisor – Invitae Consultant – GeneDx
2018-02-23 6:46:17	Christina Austin-Tse	Yes	No			
2018-02-23 11:19:42	Birgit Funke	Yes	No		My lab does actively curate variants in cardiomyopathy genes as those are part of the ACMG59 and are as such of high relevance for the test we are offering (whole genome testing for healthy individuals)	
2018-02-23 5:48:03	Olga Jarinova	Yes	No	Several manuscripts in draft but not yet published	No	One of the goals of my Expert Panel is to eventually extend frequency cut offs established for MYH7 to other cardiomyopathy genes. My team is in the final stages of preparing a manuscript that will describe results of applying frequency cut offs, similar to those recommended for MYH7, to other genes.
2018-02-23 2:23:06	James Ware	No	Yes	I have contributed to case-control studies re-assessing previously reported CM genes. I have contributed to studies evaluating the "interpretability" of variants across a wide range of CM genes. I have contributed to studies proposing specific methods for interpretation of diverse CM genes.	Our ongoing work is primarily based on new data, rather than curation. We have previously published some curation of HCM genes. We have developed the CardioClassifier tool that includes a selected gene list with curated mechanisms of action / inheritance modes etc. I am involved in the Transforming Genomic Medicine Initiative (TGMI), and have agreed to act as a (Cardiovascular) link with the Ensembl G2P initiative to coordinate curations to minimise redundancy of effort.	I contributed to CardioClassifier.org, and have received grant support to develop this platform. This is freely available for academic & UK NHS users. License fees for commercial use support ongoing development of the tool in our lab.
2018-02-22 14:16:41	John Garcia	Yes	No		no	I am a full-time employee of Invitae (salary and stock). I also hold stock options at 23andMe. I have no patents, IP, or paid consultancies.